279 related articles for article (PubMed ID: 17360080)
1. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.
Carrion R; Patterson JL; Johnson C; Gonzales M; Moreira CR; Ticer A; Brasky K; Hubbard GB; Moshkoff D; Zapata J; Salvato MS; Lukashevich IS
Vaccine; 2007 May; 25(20):4093-102. PubMed ID: 17360080
[TBL] [Abstract][Full Text] [Related]
2. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates.
Lukashevich IS; Carrion R; Salvato MS; Mansfield K; Brasky K; Zapata J; Cairo C; Goicochea M; Hoosien GE; Ticer A; Bryant J; Davis H; Hammamieh R; Mayda M; Jett M; Patterson J
Vaccine; 2008 Sep; 26(41):5246-54. PubMed ID: 18692539
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.
Zapata JC; Goicochea M; Nadai Y; Eyzaguirre LM; Carr JK; Tallon LJ; Sadzewicz L; Myers G; Fraser CM; Su Q; Djavani M; Lukashevich IS; Salvato MS
J Virol; 2014 Mar; 88(6):3058-66. PubMed ID: 24335292
[TBL] [Abstract][Full Text] [Related]
4. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; MartÃnez-Sobrido L
mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
[TBL] [Abstract][Full Text] [Related]
5. Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and Attenuation.
Johnson DM; Cubitt B; Pfeffer TL; de la Torre JC; Lukashevich IS
Viruses; 2021 Jan; 13(2):. PubMed ID: 33573250
[TBL] [Abstract][Full Text] [Related]
6. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model.
Goicochea MA; Zapata JC; Bryant J; Davis H; Salvato MS; Lukashevich IS
Vaccine; 2012 Feb; 30(8):1445-52. PubMed ID: 22234266
[TBL] [Abstract][Full Text] [Related]
8. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.
Lukashevich IS; Patterson J; Carrion R; Moshkoff D; Ticer A; Zapata J; Brasky K; Geiger R; Hubbard GB; Bryant J; Salvato MS
J Virol; 2005 Nov; 79(22):13934-42. PubMed ID: 16254329
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidate.
Zapata JC; Carrion R; Patterson JL; Crasta O; Zhang Y; Mani S; Jett M; Poonia B; Djavani M; White DM; Lukashevich IS; Salvato MS
PLoS Negl Trop Dis; 2013; 7(9):e2406. PubMed ID: 24069471
[TBL] [Abstract][Full Text] [Related]
10. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; MartÃnez-Sobrido L; de la Torre JC
mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
[TBL] [Abstract][Full Text] [Related]
11. An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity.
Zapata JC; Poonia B; Bryant J; Davis H; Ateh E; George L; Crasta O; Zhang Y; Slezak T; Jaing C; Pauza CD; Goicochea M; Moshkoff D; Lukashevich IS; Salvato MS
Virol J; 2013 Feb; 10():52. PubMed ID: 23402317
[TBL] [Abstract][Full Text] [Related]
12. Vaccine platforms to control Lassa fever.
Lukashevich IS; Pushko P
Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
[TBL] [Abstract][Full Text] [Related]
13. Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.
Maruyama J; Mateer EJ; Manning JT; Sattler R; Seregin AV; Bukreyeva N; Jones FR; Balint JP; Gabitzsch ES; Huang C; Paessler S
Vaccine; 2019 Oct; 37(45):6824-6831. PubMed ID: 31561999
[TBL] [Abstract][Full Text] [Related]
14. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.
Carnec X; Mateo M; Page A; Reynard S; Hortion J; Picard C; Yekwa E; Barrot L; Barron S; Vallve A; Raoul H; Carbonnelle C; Ferron F; Baize S
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593043
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.
Cashman KA; Wilkinson ER; Wollen SE; Shamblin JD; Zelko JM; Bearss JJ; Zeng X; Broderick KE; Schmaljohn CS
Hum Vaccin Immunother; 2017 Dec; 13(12):3010-3019. PubMed ID: 29135337
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques.
Jiang J; Banglore P; Cashman KA; Schmaljohn CS; Schultheis K; Pugh H; Nguyen J; Humeau LM; Broderick KE; Ramos SJ
Hum Vaccin Immunother; 2019; 15(9):2066-2074. PubMed ID: 31071008
[TBL] [Abstract][Full Text] [Related]
17. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.
Jiang X; Dalebout TJ; Bredenbeek PJ; Carrion R; Brasky K; Patterson J; Goicochea M; Bryant J; Salvato MS; Lukashevich IS
Vaccine; 2011 Feb; 29(6):1248-57. PubMed ID: 21145373
[TBL] [Abstract][Full Text] [Related]
18. The search for animal models for Lassa fever vaccine development.
Lukashevich IS
Expert Rev Vaccines; 2013 Jan; 12(1):71-86. PubMed ID: 23256740
[TBL] [Abstract][Full Text] [Related]
19. Attenuated Replication of Lassa Virus Vaccine Candidate ML29 in STAT-1
Johnson DM; Jokinen JD; Lukashevich IS
Pathogens; 2019 Jan; 8(1):. PubMed ID: 30650607
[TBL] [Abstract][Full Text] [Related]
20. Current research for a vaccine against Lassa hemorrhagic fever virus.
Warner BM; Safronetz D; Stein DR
Drug Des Devel Ther; 2018; 12():2519-2527. PubMed ID: 30147299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
